Wall Street analysts predict that Biocept Inc (NASDAQ:BIOC) will post earnings of ($1.71) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Biocept’s earnings. The lowest EPS estimate is ($2.40) and the highest is ($1.01). Biocept posted earnings of ($6.06) per share during the same quarter last year, which suggests a positive year over year growth rate of 71.8%. The business is expected to report its next quarterly earnings results on Thursday, November 8th.

According to Zacks, analysts expect that Biocept will report full year earnings of ($9.05) per share for the current financial year, with EPS estimates ranging from ($9.61) to ($8.49). For the next fiscal year, analysts anticipate that the company will report earnings of ($4.29) per share, with EPS estimates ranging from ($5.41) to ($3.16). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Biocept.

Biocept (NASDAQ:BIOC) last posted its earnings results on Tuesday, August 14th. The medical research company reported ($2.70) EPS for the quarter, beating the consensus estimate of ($3.30) by $0.60. Biocept had a negative return on equity of 587.80% and a negative net margin of 642.49%. The firm had revenue of $0.82 million for the quarter, compared to analysts’ expectations of $1.09 million.

BIOC has been the topic of several analyst reports. ValuEngine upgraded Biocept from a “hold” rating to a “buy” rating in a research report on Tuesday, July 10th. Dawson James reiterated a “buy” rating on shares of Biocept in a research report on Wednesday, October 3rd. Finally, Zacks Investment Research upgraded Biocept from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $0.92.

An institutional investor recently raised its position in Biocept stock. BlackRock Inc. boosted its position in shares of Biocept Inc (NASDAQ:BIOC) by 1.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 794,302 shares of the medical research company’s stock after purchasing an additional 14,403 shares during the period. BlackRock Inc. owned 34.99% of Biocept worth $159,000 at the end of the most recent reporting period.

BIOC opened at $2.39 on Friday. Biocept has a 12 month low of $2.07 and a 12 month high of $36.00. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.08 and a current ratio of 1.20. The company has a market capitalization of $5.07 million, a P/E ratio of -0.10 and a beta of 1.63.

About Biocept

Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.

Recommended Story: Growth Stocks

Get a free copy of the Zacks research report on Biocept (BIOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.